Drug
Maralixibat clinical trials
Also written LUM001 and TAK-625.
- studies test it
- 23
- open now
- 4
- in phase 3
- 7
- first study started
- 2013
Keep track of what changes. Save the maralixibat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2014 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 15
- Phase 3
- 7
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 2
Mirum Pharmaceuticals, Inc. (19) · Takeda (2) · Imperial College London (1) · Children's Hospital Los Angeles (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses maralixibat is read from its arms, and is right about nine times in ten.
Testing it · 23
- MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)Not yet recruitingPhase 2Mirum Pharmaceuticals, Inc.NCT07823127Written as Maralixibat
- Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)RecruitingPhase 4Mirum Pharmaceuticals, Inc.NCT07290257Written as Livmarli Oral Product
- Maralixibat in Patients With Cystic Fibrosis and ConstipationRecruitingPhase 2/3Children's Hospital Los AngelesNCT06413368Written as Maralixibat 9.5 MG/ML [Livmarli]
- Maralixibat for Intrahepatic Cholestasis of PregnancyNot yet recruitingPhase 2Imperial College LondonNCT07389031Written as Maralixibat
- Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)Active, not recruitingPhase 3Mirum Pharmaceuticals, Inc.NCT06553768Written as Maralixibat
- An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)CompletedPhase 3Mirum Pharmaceuticals, Inc.NCT04185363Written as Maralixibat
- A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).CompletedPhase 2Mirum Pharmaceuticals, Inc.NCT04729751Written as Maralixibat
- A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)CompletedPhase 3TakedaNCT05543174Written as TAK-625
- A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)CompletedPhase 3TakedaNCT05543187Written as TAK-625
- MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat StudyCompletedPhase 2Mirum Pharmaceuticals, Inc.NCT04168385Written as Maralixibat
- Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiCompletedPhase 2Mirum Pharmaceuticals, Inc.NCT04524390Written as Maralixibat
- A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)CompletedPhase 3Mirum Pharmaceuticals, Inc.NCT03905330Written as Maralixibat
- Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic CholestasisCompletedPhase 2Mirum Pharmaceuticals, Inc.NCT02057718Written as LUM001 (Maralixibat)
- An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)CompletedPhase 2Mirum Pharmaceuticals, Inc.NCT02047318Written as LUM001 (Maralixibat)
- Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)CompletedPhase 2Mirum Pharmaceuticals, Inc.NCT02160782Written as LUM001 (Maralixibat)
- An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille SyndromeCompletedPhase 2Mirum Pharmaceuticals, Inc.NCT02117713Written as LUM001 (Maralixibat)
- Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid ExcretionCompletedPhase 1Mirum Pharmaceuticals, Inc.NCT02475317Written as Maralixibat
- Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing CholangitisCompletedPhase 2Mirum Pharmaceuticals, Inc.NCT02061540Written as LUM001
- Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille SyndromeCompletedPhase 2Mirum Pharmaceuticals, Inc.NCT01903460Written as LUM001
- Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary CirrhosisCompletedPhase 2Mirum Pharmaceuticals, Inc.NCT01904058Written as LUM001
Codes
What other systems call maralixibat · ClinicalTrials.gg INT001908
- MeSH (NLM) C000722912maralixibatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) UYB6UOF69LMARALIXIBATConfirmed FDA, NLM, Wikidata
- RxNorm 2571074One source FDA
- Wikidata Q27291331maralixibatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170148MaralixibatOne source FDA
- DrugBank DB16226One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722912 | maralixibat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | UYB6UOF69L | MARALIXIBAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2571074 | — | One source FDA |
| Wikidata | Q27291331 | maralixibat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170148 | Maralixibat | One source FDA |
| DrugBank | DB16226 | — | One source Wikidata |
Also registered as maralixibat chloride (UNII V78M04F0XC · RxNorm 2571073).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.